Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rademikibart for Acute Exacerbation in Asthma or COPD With Type 2 Inflammation
NCT07705737Phase 2Recruiting
- Sponsor
- Connect Biopharma
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of rademikibart in asthma, chronic obstructive pulmonary disease (COPD), sponsored by Connect Biopharma. Started Aug 2026; status: recruiting.
02
Drugs
rademikibart
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07705737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705737.